Background: Evidence supporting the possible causal association of myopericarditis with the coronavirus disease (COVID-19) vaccine has mainly come from case reports. Epidemiological evidence indicating an increased relative risk for myopericarditis after COVID-19 vaccination is lacking. Therefore, this study aimed to identify and assess all confirmed COVID-19 vaccine- related cases of myopericarditis presenting to major cardiac centers in the Eastern Region of Saudi Arabia, before and after the introduction of the COVID-19 vaccine.

Methods: According to case definition, the hospital's information system database detected all confirmed cases at two main cardiac centers.

Results: Of the 18 confirmed myocarditis and myopericarditis cases detected after the administration of COVID-19 vaccines, three were possibly related to COVID-19 immunization. The first case was of myopericarditis following a third dose of mRNA-1273. The second case was myocarditis, which occurred seven days after the first dose of AstraZeneca. The third case was myocarditis, which occurred 12 days after the third dose of BNT162b2. A cardiologist carefully evaluated the cases using recognized protocols and case definitions to demonstrate a direct relationship with vaccination consequences rather than coincidence.

Conclusion: We found no difference in the occurrence of myocarditis and myopericarditis after the COVID-19 vaccine compared with the background rate during a similar period (P = 0.9783). The incidences of myocarditis and myopericarditis following immunization were low. The advantages of the COVID-19 vaccination outweigh the risk of myopericarditis.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11283260PMC
http://dx.doi.org/10.2147/IJGM.S467586DOI Listing

Publication Analysis

Top Keywords

myopericarditis covid-19
12
covid-19 vaccination
12
myocarditis myopericarditis
12
covid-19
9
eastern region
8
region saudi
8
saudi arabia
8
myopericarditis
8
covid-19 vaccine
8
risk myopericarditis
8

Similar Publications

Unlabelled: mRNA vaccines represent a milestone in the history of vaccinology, because they are safe, very effective, quick and cost-effective to produce, easy to adapt should the antigen vary, and able to induce humoral and cellular immunity.

Methods: To date, only two COVID-19 mRNA and one RSV vaccines have been approved. However, several mRNA vaccines are currently under development for the prevention of human viral (influenza, human immunodeficiency virus [HIV], Epstein-Barr virus, cytomegalovirus, Zika, respiratory syncytial virus, metapneumovirus/parainfluenza 3, Chikungunya, Nipah, rabies, varicella zoster virus, and herpes simplex virus 1 and 2), bacterial (tuberculosis), and parasitic (malaria) diseases.

View Article and Find Full Text PDF

Is it just another case of vaccine-induced myocarditis? A case report and key insights.

Eur Heart J Case Rep

November 2024

Department of Cardiology, Homerton Healthcare NHS Foundation Trust, Homerton Row, London, UK.

Article Synopsis
  • - The rising incidence of myopericarditis cases has been observed alongside an increase in COVID-19 vaccinations, highlighting the need for a thoughtful approach to these occurrences in the clinical setting.
  • - A case involving a woman in her 50s who developed symptoms of myopericarditis after receiving the AstraZeneca vaccine was diagnosed with an infected right atrial thrombus, leading to treatment with antibiotics and anticoagulation.
  • - This case underscores the necessity for multi-modal imaging and regular follow-up assessments in diagnosing and managing vaccine-related myopericarditis, along with considering additional procedures like endomyocardial biopsy for improved accuracy.
View Article and Find Full Text PDF

Introduction: The need to understand the global burden of heart failure following the pandemic has arisen as a result of an increase in papers that support cardiac involvement in coronavirus disease 2019 (COVID-19). Therefore, the current study aims to provide a more thorough explanation of the function and use of cardiac biomarkers in dead and alive COVID-19 patients.

Methods: All patients who were referred and admitted to Razi Hospital, Ahvaz, Iran, from March 2020 to March 2021 with a diagnosis of COVID-19 were included in this study.

View Article and Find Full Text PDF
Article Synopsis
  • The emergence of SARS-CoV-2 in 2019 led to widespread health challenges, revealing gaps in understanding the long-term effects of COVID-19, particularly on cardiovascular health.
  • Long COVID-19 can cause serious cardiovascular issues such as chest pain, arrhythmias, heart failure, and even sudden cardiac death, making it crucial for healthcare providers to assess these risks during preoperative evaluations for affected patients.
  • This literature review aims to enhance knowledge about the cardiovascular impacts of long COVID-19 and emphasize the need for thorough presurgical cardiac clearance amidst limited current evidence.
View Article and Find Full Text PDF

The incidence of myocarditis and pericarditis has been documented in adolescents after COVID-19 vaccinations. This study aims to assess the risk of myopericarditis in adolescents following COVID-19 vaccination, using a meta-analysis of the published cases. We performed a comprehensive literature search of the following databases on July 5, 2023: MEDLINE, EMBASE, PubMed, and the Cochrane Library.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!